Evidence map›Paper›PMID 32091549›Full record

ArticleJAMA neurology2020

Assessment of Demographic, Genetic, and Imaging Variables Associated With Brain Resilience and Cognitive Resilience to Pathological Tau in Patients With Alzheimer Disease.

Rik Ossenkoppele, Chul Hyoung Lyoo, Jonas Jester-Broms, Carole H Sudre, Hanna Cho, Young Hoon Ryu, Jae Yong Choi, Ruben Smith, Olof Strandberg, Sebastian Palmqvist and 7 more

Open access · hybridAbstract readMulticenter Study
In one paragraph

Article in JAMA neurology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 115 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
115citing papers in PubMed, 1 pooled it
12.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

115 citing papers in PubMed, 1 synthesis or guideline pooled it, 135 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Evaluation of [Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism · 2021
    Trial
  5. Article
  6. Article
  7. Article
  8. Article
  9. Sex specificity of resistance to caTAUstrophe.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Article
  10. Review
  11. Purpose in life and blood-based biomarkers of brain health.The journals of gerontology. Series B, Psychological sciences and social sciences · 2026
    Article
  12. Stable neuronal representations underlie cognitive resilience to Alzheimer's disease pathology.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Article
  13. MethylCog predicts six-year cognitive ability beyond blood-based ADRD biomarkers.medRxiv : the preprint server for health sciences · 2026
    Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article

55 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 8 institutions in 5 countries.

Rik OssenkoppeleLund University, Clinical Memory Research Unit, Lund, Sweden.
Chul Hyoung LyooGangnam Severance Hospital, Department of Neurology, Yonsei University College of Medicine, Seoul, South Korea.
Jonas Jester-BromsLund University, Clinical Memory Research Unit, Lund, Sweden.
Carole H SudreKing's College London School of Biomedical Engineering and Imaging Sciences, London, United Kingdom.
Hanna ChoDementia Research Centre, Department of Neurodegenerative Disease, University College London Institute of Neurology, London, United Kingdom.
Young Hoon RyuGangnam Severance Hospital, Department of Nuclear Medicine, Yonsei University College of Medicine, Seoul, South Korea.
Jae Yong ChoiGangnam Severance Hospital, Department of Nuclear Medicine, Yonsei University College of Medicine, Seoul, South Korea.
Ruben SmithLund University, Clinical Memory Research Unit, Lund, Sweden.
Olof StrandbergLund University, Clinical Memory Research Unit, Lund, Sweden.
Sebastian PalmqvistLund University, Clinical Memory Research Unit, Lund, Sweden.
Joel KramerMemory and Aging Center, Department of Neurology, University of California, San Francisco.
Adam L BoxerMemory and Aging Center, Department of Neurology, University of California, San Francisco.
Maria L Gorno-TempiniMemory and Aging Center, Department of Neurology, University of California, San Francisco.
Bruce L MillerMemory and Aging Center, Department of Neurology, University of California, San Francisco.
Renaud La JoieMemory and Aging Center, Department of Neurology, University of California, San Francisco.
Gil D RabinoviciMemory and Aging Center, Department of Neurology, University of California, San Francisco.
Oskar HanssonLund University, Clinical Memory Research Unit, Lund, Sweden.
Lund University · SEUniversity Memory and Aging Center · USGangnam Severance Hospital · KRUniversity College London · GBUniversity of California, San Francisco · USAmsterdam Neuroscience · NLSkåne University Hospital · SEYonsei University · KR

Funding

TDP-43 Loss-of-Function: Biology to BiomarkersP01AG019724 · NIA · UNIVERSITY OF PENNSYLVANIA · PI Jennifer Merrilees · 2002 to 2026
$67.2M
Research Education ComponentP30AG062422 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Gil Dan Rabinovici · 2019 to 2026
$36.9M
PrPSc SPECIFIC INTERACTION WITH NOVEL PrP-Fc FUSION PROTEINSP50AG023501 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI HUANG, YADONG · 2004 to 2018
$27.1M
The Four Repeat Tauopathy Neuroimaging InitiativeR01AG038791 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI BOXER, ADAM L. · 2010 to 2020
$18.1M
Progressive Aphasia Cognition Anatomy and ProgressionR01NS050915 · NINDS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MARIA LUISA GORNO TEMPINI · 2004 to 2026
$11.0M
Training - The Frontotemporal Lobar Degeneration Clinical Research ConsortiumU54NS092089 · NINDS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI BOXER, ADAM L. · 2014 to 2018
$6.4M
Connectomic imaging in familial and sporadic frontotemporal degenerationU01AG052943 · NIA · UNIVERSITY OF PENNSYLVANIA · PI GORNO TEMPINI, MARIA LUISA, GROSSMAN, MURRAY · 2016 to 2019
$5.9M
Dynamic Brain Imaging of Speech in Primary Progressive AphasiaR01NS100440 · NINDS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MARIA LUISA GORNO TEMPINI, John Francis Houde · 2017 to 2026
$3.6M
Early Age-of-Onset AD: Clinical Heterogeneity and Network DegenerationR01AG045611 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI RABINOVICI, GIL DAN · 2014 to 2018
$3.1M
Training program in the neurology of language and neurodegenerative aphasiasK24DC015544 · NIDCD · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GORNO TEMPINI, MARIA LUISA · 2016 to 2025
$1.9M
Primary Progessive Aphasia: Cognition, Anatomy and ProgressionR56NS050915 · NINDS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GORNO TEMPINI, MARIA LUISA · 2008 to 2008
$315k
NIA NIH HHS P01 AG019724NIA NIH HHS P30 AG062422NIA NIH HHS P50 AG023501NIA NIH HHS R01 AG038791NIA NIH HHS R01 AG045611NIA NIH HHS U01 AG052943NIDCD NIH HHS K24 DC015544NINDS NIH HHS R01 NS050915NINDS NIH HHS R01 NS100440NINDS NIH HHS R56 NS050915NINDS NIH HHS U54 NS092089
6 · The paper itself

Abstract

Importance: Better understanding is needed of the degree to which individuals tolerate Alzheimer disease (AD)-like pathological tau with respect to brain structure (brain resilience) and cognition (cognitive resilience). Objective: To examine the demographic (age, sex, and educational level), genetic (APOE-ε4 status), and neuroimaging (white matter hyperintensities and cortical thickness) factors associated with interindividual differences in brain and cognitive resilience to tau positron emission tomography (PET) load and to changes in global cognition over time. Design, Setting, an Participants: In this cross-sectional, longitudinal study, tau PET was performed from June 1, 2014, to November 30, 2017, and global cognition monitored for a mean [SD] interval of 2.0 [1.8] years at 3 dementia centers in South Korea, Sweden, and the United States. The study included amyloid-β-positive participants with mild cognitive impairment or AD dementia. Data analysis was performed from October 26, 2018, to December 11, 2019. Exposures: Standard dementia screening, cognitive testing, brain magnetic resonance imaging, amyloid-β PET and cerebrospinal fluid analysis, and flortaucipir (tau) labeled with fluor-18 (18F) PET. Main Outcomes and Measures: Separate linear regression models were performed between whole cortex [18F]flortaucipir uptake and cortical thickness, and standardized residuals were used to obtain a measure of brain resilience. The same procedure was performed for whole cortex [18F]flortaucipir uptake vs Mini-Mental State Examination (MMSE) as a measure of cognitive resilience. Bivariate and multivariable linear regression models were conducted with age, sex, educational level, APOE-ε4 status, white matter hyperintensity volumes, and cortical thickness as independent variables and brain and cognitive resilience measures as dependent variables. Linear mixed models were performed to examine whether changes in MMSE scores over time differed as a function of a combined brain and cognitive resilience variable. Results: A total of 260 participants (145 [55.8%] female; mean [SD] age, 69.2 [9.5] years; mean [SD] MMSE score, 21.9 [5.5]) were included in the study. In multivariable models, women (standardized β = -0.15, P = .02) and young patients (standardized β = -0.20, P = .006) had greater brain resilience to pathological tau. Higher educational level (standardized β = 0.23, P < .001) and global cortical thickness (standardized β = 0.23, P < .001) were associated with greater cognitive resilience to pathological tau. Linear mixed models indicated a significant interaction of brain resilience × cognitive resilience × time on MMSE (β [SE] = -0.235 [0.111], P = .03), with steepest slopes for individuals with both low brain and cognitive resilience. Conclusions and Relevance: Results of this study suggest that women and young patients with AD have relative preservation of brain structure when exposed to neocortical pathological tau. Interindividual differences in resilience to pathological tau may be important to disease progression because participants with both low brain and cognitive resilience had the most rapid cognitive decline over time.

Indexed as

Alzheimer DiseaseAgedAge FactorsBrainCognitionCognitive ReserveCross-Sectional StudiesDisease ProgressionFemaleHumansImage Interpretation, Computer-AssistedLongitudinal StudiesMagnetic Resonance ImagingMaleNeuroimagingPositron Emission Tomography Computed Tomographytau Proteins

Identifiers

PMID32091549
PMCPMC7042808
OpenAlexW3007734058

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.